NCT02046421View on ClinicalTrials.gov

Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions
Male Breast CancerRecurrent Breast CancerRecurrent Fallopian Tube CancerRecurrent Ovarian Epithelial CancerRecurrent Primary Peritoneal Cavity CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast Cancer
Interventions
DRUG

mifepristone

Given PO

DRUG

carboplatin

Given IV

DRUG

gemcitabine hydrochloride

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (2)

60201

NorthShore University HealthSystem, Evanston

60637-1470

University of Chicago Comprehensive Cancer Center, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER

NCT02046421 - Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter